Drugs / Jinlida granules
Jinlida granules
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06495814 | Jul 2024 → Dec 2025 overdue | glucose intolerance | Fengmei Lian | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02035644 | Feb 2014 → Feb 2015 | hyperlipidemia, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jinlida granules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02035644 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes” NCT02035644 ↗ |
| Route | Oral | “taken with hot water.” NCT06495814 ↗ |